Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

Adoptive Cell Therapies and Engagers

Cancer Vaccines, Oncolytic Viruses, and Beyond

Immune Checkpoint Blockade and Other Immunotherapies

Late-breaking: Tumor Immunology: Checkpoints, Prevention, And Treatment

Molecular Determinants of Tumor Responses

(793) Defining Heterogeneity of CAR T cell populations to treat B16F10 melanoma

(794) Pre-clinical Development of a Novel CAR-T Therapy Targeting TIM-1 for Treating Solid Tumors

(795) Engineering cytokine/antibody fusion proteins that selectively stimulate immune effector populations for cancer immunotherapy

(796) BACH2 dosage establishes the hierarchy of stemness and finetunes antitumor immunity in CAR T cells

(797) Single-cell profiling of CSF immune dynamics following intracranial B7-H3 CAR T cell therapy for pediatric brain tumors

(798) Targeting NOX1 to Reprogram T Cell Activation and Metabolism for Enhanced CAR T Efficacy

(799) Lymphoid Tissue-Activated Donor T cells (LADTs) for Improved Donor Lymphocyte Infusion (DLI) against Blood Cancers

(800) RGS16 as a Therapeutic Target to Overcome TGFβ-Induced Resistance in Adoptive T Cell Therapies

(801) HaloCAR - a Universal Chimeric Antigen Receptor (CAR) Programmable by Chloroalkane-Conjugated Adaptors

(802) Leveraging modular TriKE-PACC molecules capable of dual-antigen targeting to enhance NK-cell immunotherapy in AML

(803) Uncovering Synergistic Pathways for T Cell Stemness and Improved Adoptive Cell Therapy Outcomes

(804) Use of a 50-Marker Mass Cytometry Intracellular Cytokine Staining Panel Reveals Unforeseen Functional Diversity Within Cell Therapy Products

(805) Developing Novel Bispecific T-cell Engager Therapy by Concurrent Targeting GARP on Cancer Cells and Regulatory T cells

(806) T-bet CAR T cells: A new avenue for NSCLC therapy analyzed in lung cancer-derived organoids

(807) Relationship between CAR spatial organization and CAR T cell function revealed by imaging flow cytometry and transcriptomic profiling

(808) Trogocytosis as a Cellular method for Identification of Antigen specific T cells in Adoptive Cellular Therapy

(809) Bispecific T Cell Engagers Sensitize the Glioblastoma Tumor Microenvironment to Immune Checkpoint Blockade Responsiveness

(810) Reoxygenating the Tumor Microenvironment with Biomimetic Hemoglobin Nanoparticles Enhances Chemo, CAR-T, and Gene Therapies

(811) Engagement of the T cell receptor against an oncolytic virus generates a population of hypereffector CAR T cells with potent antitumor activity

(811) Expanding the Antigen Targeting of CAR T Cells via a Universal Bispecific T cell Engager

(812) An AAV9-Based Strategy for the Treatment of Cervical Dysplasia

(812) TcBuster-M™ Enables Efficient Non-Viral Delivery of Multicistronic CD19-CAR Constructs in T and NK Cells

(813) mRNA Nanotherapy targeting Kv1.3 channels enables in vivo reprogramming of T cells for cancer therapy

(813) Simplifying CD19 CAR Detection: A Bright Single-Step Solution for Flow Cytometry

(814) Cancer Immunotherapy with IL-15Rα-armed Oncolytic Myxoma Virus Enhances Antitumor Immunity Against Solid Tumors

(814) Decoding the Hallmark Features of Modular CAR Domains and Their Impact on CAR T Cell Tumoricidal Activity

(815) Messenger RNA vaccination produces functionally robust yet peripherally restricted tumor-specific cytolytic effector cells

(815) T-ALL Elicits Robust T Cell Responses Despite Low Tumor Mutational Burden in multiple tissues with distinct TMEs

(816) Allogeneic CAR-T activity enabled by knockout of LCK

(817) Antibody-mediated CAR T Platform for Targeting Tumor Cells and the Tumor Microenvironment

(817) CRISPR-Based Gene Screening in Oncolytic Vaccinia Virus

(818) CD3-epsilon/delta heterodimer recombinant protein induced diverse antibodies binding to Jurkat cells and primary T cells in mice

(818) Roadmap of MCPyV T-antigens for off-the-shelf therapeutic MCC vaccine development

(819) The potential application of bioflavonoids in cancer treatment

(824) Unlocking Therapeutic Vulnerabilities in Leukemia with CRISPR-Based Screens

(825) Mitochondrial ATP production links chromatin accessibility to T cell differentiation and function

(827) Effect of small molecule inhibitors of IRF3 and TBK1 signaling pathways on ovarian cancer cells

(828) Effect of inhibiting pathogen recognition receptor function with small molecules on ovarian cancer cells in vitro

(829) Microplastics Trigger Antigen Presentation and CXCL1-Mediated Inflammation in Glioma Tumor-Associated Myeloid Cells.

(830) The transcription co-regulator OCA-B/Pou2af1 differentially controls autoimmunity and tumor immunity

(831) Metformin fails to replicate the metabolic phenotype of Compound 991 treatment in primary human T cells

(835) Neurotrophic receptor GFRα2 drives pro-metastatic programming of Kupffer cells in liver metastases

(836) Lysophosphatidylcholine (LPC 18:2) Reprograms the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade

(837) Checkpoint Blockade Selects Innate-Programmed Cytotoxic T Cells with Pathogenic TCR Features in Immune-Related Arthritis

(838) B Cells Undergo Transcriptional Changes Following Autoimmune Sicca Development in Melanoma Patients Treated with Immune Checkpoint Inhibitors

(839) nELISA high-throughput proteomic profiling of RADIOHEAD: insights from the largest plasma study of patients receiving checkpoint inhibitor therapy

(840) Mechanisms of CD070, an Active Compound from Chinese Herbal Medicine, in Regulating and Inhibiting PD-1 Expression

(841) A new TLR-7 agonist stimulates anticancer immunity through the activation of epithelial cell cytokine response.

(842) Targeting a cancer cell Interferon-TBK1 signaling axis attenuates inflammatory memory mediated resistance to immune checkpoint blockade

(843) NUPR1 promotes macrophage immunosuppression and resistance to immunotherapy in a novel kidney cancer model

(844) Evaluating immunotherapy response in bladder cancer patients by spatially interrogating PD-1/PD-L1 interaction

(845) Reprogramming the tumor microenvironment: endowing T with the ability to degrade the extracellular matrix

(846) ‘’Do not eat me’’: LILRB4 signaling as a novel macrophage immunotherapy in lung cancer

(847) Diverse resident memory T-cell subsets differentiate in tumors to promote antitumor immunity and response to immune checkpoint blockade immunotherapy

(848) Enhancing antibody delivery to the brain using antiviral immune response

(849) VERU-111 modulates gut microbiota and offers an advantage in colorectal cancer therapeutics

(850) PD-L1 facilitates transcription of anti-apoptotic genes IL-8, Bcl3 and STAT1, resulting in increased proliferation of ovarian cancer cells

(851) Blocking the VISTA/LRIG1 axis ‎enhances antitumor CD8+ T cell responses and controls anaplastic ‎thyroid tumor progression

(852) Non-Competing Clones Overcome Therapeutic Antibody Interference in Flow Cytometry

(853) Siglec-9 is a functional inhibitory receptor for B7-H3 that regulates anti-tumor immunity

(854) Use of bacterial chassis for the intratumoral delivery of a super-interferon gamma in a breast cancer model

(855) The VISTA–LRIG1 Axis Integrates Myeloid and T Cell Suppression to Drive Immune Resistance in Triple-Negative Breast Cancer

(856) Exploring the Role of Natural Anti-PD-L1 antibodies in Shaping the Anti-Tumor Immune Response to Neoadjuvant Chemo-Immunotherapy in NSCLC

(857) Manganese-Polydopamine Nano-Immunomodulator Synergistically Activates the STING Pathway and Pyroptosis for Renal Cell Carcinoma Immunotherapy

(858) Dietary alterations in gut microbiota impact anti-tumor immunity: towards novel strategies to boost cancer immunotherapy.

(859) The FOCUS19 study: Efficacy of an oral PD-L1 inhibitor combined with an oral FGF19 in advanced hepatocellular carcinoma after 1st+ line treatment

(860) Humoral immunity against gut commensals governs their prevalence and influences patient clinical outcome

(861) Improved natural killer cell targeting of prostate carcinoma with ATR inhibitor tuvusertib in combination with IL-15 receptor superagonist N-803

(862) T-Cell Acute Lymphoblastic Leukemia (T-ALL) Drives Robust T Cell Responses That Can Be Harnessed With aCD40 and aPD1 Combination Therapy

(864) Activating systemic immunity through engineered lymph node-homing T cells

(865) Development and Validation of High Sensitivity SimpleStep Ignite® ELISAs for Quantitative Measurement of Human Immune Checkpoint Proteins

(866) Investigating immune checkpoint blockade of LY-6A protein as cancer immunotherapy in mice.

(867) Targeting CD160 as an Immunotherapy Approach to modulate tumour Angiogenesis and Improve Outcomes in Triple-Negative Breast Cancer

(868) Mechanisms Underlying LAG3 Immune Checkpoint Function

(869) Structure-Guided Computational Engineering of pH-Selective B7-H3 CAR-T Cells to Mitigate On-Target/Off-Tumor Toxicity

(870) Evaluation of Salmonella bearing Tumor-targeting Peptides for Cancer Therapy